CardieX Ltd, an Australian-founded health technology company, is at the forefront of creating a notable impact on the global health scene through its innovative biomarker technologies and digital solutions. The company’s primary focus lies in the field of cardiovascular health, but its contributions extend further and encompass a range of prevalent health disorders. CardieX’s significant accomplishment is its ability to create advanced, yet straightforward solutions to some of the most widely prevalent health disorders in the world.
A Highlight of CardieX’s Biomarker Technologies:
Garnering recognition in the health fraternity, CardieX is enhancing its technological prowess by introducing robust and efficient biomarker technologies. These advancements play pivotal roles in dealing with the world’s leading health disorders. By analysing an individual’s biomarkers—certain biochemical substances that indicate the normal or abnormal functioning of the body—CardieX can detect risky health conditions at an early stage. This timely detection helps in preventive care and spontaneous intervention in disease progression.
Central to CardieX’s biomarker offering is its patented SphygmoCor® technology, a device that measures central blood pressure and arterial stiffness, providing crucial insights into cardiovascular health. Notably, arterial stiffness is a significant marker for heart disease, stroke, and other related complications. SphygmoCor® stands as a shining example of how CardieX has packaged cutting-edge biomarker technology in a user-friendly, worthwhile solution for the masses.
Unveiling Digital Solutions for World’s Largest Health Disorders:
Parallel to its work with biomarker technologies, CardieX investing heavily in digital solutions. The majority of these solutions are centred around dealing with cardiovascular disorders – the number one cause of global deaths. In response to this ongoing global crisis, the company’s digital solutions aim to mitigate the prevalence of heart complications and enhance the quality of cardiac care.
A key player in this digital initiative is the company’s consumer health joint venture, ATCOR.X, which aims to develop a cutting-edge digital health platform. The platform combines biomarker insights, data analysis, artificial intelligence, and wearable technologies to provide individuals with immediate health data and predictive analytics.
The company’s advancing technology, Blumio, uses sensor-based solutions to read a person’s arterial blood pressure, without the usage of a cuff. This non-invasive method renders the process less daunting and more comfortable for patients, all while providing comprehensive health data that can be adjusted accordingly in their daily lives.
Additionally, CardieX’s software, CorMetric, extends its services to the insurance sector helping insurance underwriters assess the risk of cardiovascular diseases in their clients. CorMetric uses a risk algorithm, inputting relevant data to provide an overall picture of cardiovascular health. The software is tuned on the basis of a large database of SphygmoCor® measurements, proving instrumental in insurance risk assessment.
IMPACT-AFib, another CardieX digital technology catering to cardiovascular health, provides personalised management plans for atrial fibrillation patients. This supervising digital tool allows medical practitioners to thoughtfully prescribe anticoagulants, depending on the risk factors identified.
While its focus is primarily on cardiovascular health, CardieX has an open vision for the future to extend these solutions to other major health issues such as diabetes, stroke, obesity, and mental health disorders. Thereby, CardieX is committed to transforming the healthcare landscape with its revolutionary biomarker technologies and digital solutions, not only within the ambit of cardiology but also branching out to cater to the world’s largest health disorders.
